查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771491

全球微残留疾病检测市场：市场规模、份额、趋势分析（按技术、癌症类型、最终用途和地区）、细分市场预测（2025-2030 年）

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Cancer Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 320 Pages | 商品交期: 2-10个工作天内

价格

微残留疾病检测市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球微小残留疾病检测市场规模预计到2030年将达到45亿美元，2025年至2030年的复合年增长率为10.1%。

MRD检测作为一种新型的诊断和预后评估方法，将有助于精准制定治疗方法，以治疗各类骨髓恶性肿瘤。治疗结果的评估对于指定癌症治疗制度的成功实施至关重要。

MRD 产生的分子资讯对于更好地理解癌症病理并最终优化治疗效果至关重要。因此，MRD 检测越来越多地被用作众多肿瘤学临床试验的终点分析步骤，并且还能有效记录个体基因特征导致的治疗结果差异。例如，2020 年 11 月，Adaptive Biotechnologies Corporation 与葛兰素史克公司合作，使用 clonoSEQ 检测方法评估葛兰素史克血液学药物治疗后残留的癌细胞。

手术切除肿瘤并结合其他相关疗法并不一定意味着癌细胞被完全清除。癌细胞的痕迹可能残留在身体的某些部位和血液中。诊断这些残留细胞对于确定是否需要进一步化疗或放射线治疗至关重要。研究人员正在设计能够有效侦测MRD的非侵入性检测方法。例如，2022年2月，C2i Genomics公司的一项血液检测对肿瘤外科手术后残留的癌细胞进行了定量分析。这项C2inform检测也已获得CE标誌认证，并在欧洲以「软体即医疗设备」MRD检测的形式提供。

癌症药物可根据相关临床证据进行有效定制，避免癌细胞滞留，并根据个体的具体进展进行个体化治疗。大量研究支持考虑个体基因特征以获得有效治疗。例如，2022年10月，Adaptive Biotechnologies Corporation与Epic合作，以增加血癌患者MRD监测的可近性。此外，2021年2月，Natera Inc.与Personalis Inc.合作，透过整合NeXT肿瘤分析（由Personalis生产）和个人化ctDNA平台Signatera诊断产品（由Natera, Inc.生产），有效地设计治疗监测方案并评估MRD，从而了解个人化癌症治疗的效果。

微残留疾病检测市场报告重点

  • 从技术角度来看，由于流式细胞技术检测具有高灵敏度和广泛的适用性，2024 年流式细胞仪在微小残留疾病检测市场中占据主导地位。
  • 根据癌症类型，由于骨髓恶性肿瘤盛行率不断上升，骨髓恶性肿瘤在 2024 年占据了市场主导地位，收益占有率为 68.58%。
  • 根据最终用途，医院和专科诊所将成为 2024 年产生最高收益的部分。
  • 由于报销制度的改善以及该地区骨髓恶性肿瘤的盛行率不断上升，预计 2024 年北美将在微小残留疾病检测市场占据主导地位。

目录

第一章 分析方法与范围

第二章执行摘要

3. 微残留疾病检测市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 微残留疾病检测市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章微残留疾病检测市场：依技术分類的估计与趋势分析

  • 按技术分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球微残留病检测市场展望（按技术）
  • 市场规模预测及趋势分析（2018年及2030年）
    • 流式细胞技术
    • 聚合酵素链锁反应（PCR）
    • 次世代定序（NGS）
    • 其他的

第五章微残留疾病检测市场：按癌症类型估计和趋势分析

  • 癌症类型市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球微残留疾病检测市场：癌症类型展望
  • 市场规模预测及趋势分析（2018年及2030年）
    • 造血系统恶性肿瘤
    • 固态肿瘤

第六章微残留疾病检测市场：依最终用途的估计与趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球微小残留疾病检测市场：依最终用途分類的展望
  • 市场规模预测及趋势分析（2018年及2030年）
    • 医院和专科诊所
    • 学术研究所
    • 诊断实验室
    • 其他的

第七章微残留疾病检测市场：区域估计与趋势分析

  • 按技术分類的市场占有率（2024 年和 2030 年）
  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 市场规模预测及趋势分析（2018年及2030年）
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2024年）
    • Exact Sciences Corporation.
    • GRAIL, LLC
    • Veracyte, Inc.
    • Natera, Inc.
    • Guardant Health
    • F. Hoffmann-La Roche Ltd
    • FOUNDATION MEDICINE, INC.
    • QIAGEN
    • mdxhealth
    • Bio-Techne.
Product Code: GVR-4-68040-016-3

Minimal Residue Disease Testing Market Growth & Trends:

The global minimal residual disease testing market size is estimated to reach USD 4.50 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimal Residue Disease Testing Market Report Highlights:

  • By technology, the flow cytometry segment held a dominant share in the minimal residual disease testing market in 2024, owing to the high sensitivity and wide applicability of MRD testing.
  • By cancer type, the hematological malignancy cancer dominated the market with a revenue share of 68.58% in 2024, owing to the increasing prevalence of hematological malignancy.
  • By end-use, the hospitals and specialty clinics segment is the highest revenue-generating segment in 2024, owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics.
  • North America dominated the minimal residual disease testing market in 2024, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Cancer Type
    • 1.2.3. End use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology Outlook
    • 2.2.2. Test Type Outlook
    • 2.2.3. Cancer Type Outlook
    • 2.2.4. End use Outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Minimal Residual Disease Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Minimal Residual Disease Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Minimal Residual Disease Testing Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Minimal Residual Disease Testing Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Flow Cytometry
      • 4.4.1.1. Flow Cytometry market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Polymerase Chain Reaction (PCR)
      • 4.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Next Generation Sequencing (NGS)
      • 4.4.3.1. Next Generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Minimal Residual Disease Testing Market: Cancer Type Estimates & Trend Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Minimal Residual Disease Testing Market by Cancer Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hematological Malignancy
      • 5.4.1.1. Hematological Malignancy market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Leukemia
        • 5.4.1.2.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Lymphoma
        • 5.4.1.3.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Solid Tumors
      • 5.4.2.1. Solid Tumors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Minimal Residual Disease Testing Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Minimal Residual Disease Testing Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals and Specialty Clinics
      • 6.4.1.1. Hospitals and Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Academic and Research Institutes
      • 6.4.2.1. Academic and Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Diagnostic Laboratories
      • 6.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Minimal Residual Disease Testing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Exact Sciences Corporation.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GRAIL, LLC
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Veracyte, Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Natera, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Guardant Health
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F. Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. FOUNDATION MEDICINE, INC.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. QIAGEN
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. mdxhealth
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Bio-Techne.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 7 Global Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 11 North America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12 U.S Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 13 U.S Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 14 U.S Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 19 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 23 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 25 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 27 UK Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 29 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 33 France Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 38 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 39 Spain Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 41 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 44 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 46 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 47 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 48 Norway Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 54 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 55 Japan Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 58 China Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 60 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 61 India Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 64 South Korea Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 66 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 67 Australia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 69 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 70 Thailand Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 73 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 74 Latin America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 77 Brazil Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 93 UAE Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Minimal Residual Disease Testing: market outlook
  • Fig. 14 Minimal Residual Disease Testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook.
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Minimal Residual Disease Testing driver impact
  • Fig. 20 Minimal Residual Disease Testing restraint impact
  • Fig. 21 Minimal Residual Disease Testing strategic initiatives analysis
  • Fig. 22 Minimal Residual Disease Testing: Technology movement analysis
  • Fig. 23 Minimal Residual Disease Testing: Technology outlook and key takeaways
  • Fig. 24 Flow Cytometry market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 25 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 26 Next Generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 28 Minimal Residual Disease Testing: Cancer movement analysis
  • Fig. 29 Minimal Residual Disease Testing: Cancer outlook and key takeaways
  • Fig. 30 Hematological Malignancy market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 31 Leukemia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 32 Lymphoma market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 33 Solid Tumors market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 34 Minimal Residual Disease Testing: End use movement analysis
  • Fig. 35 Minimal Residual Disease Testing: End use outlook and key takeaways
  • Fig. 36 Hospitals & Specialty Clinics market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 37 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 38 Academic and Research Institutions market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 40 Global minimal residual disease testing market: Regional movement analysis
  • Fig. 41 Global minimal residual disease testing market: Regional outlook and key takeaways
  • Fig. 42 Global minimal residual disease testing market shares and leading players
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 45 U.S.
  • Fig. 46 U.S. market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 47 Canada
  • Fig. 48 Canada market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 49 Mexico
  • Fig. 50 Mexico market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 57 France
  • Fig. 58 France market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 66 Sweden
  • Fig. 67 Sweden market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 68 Norway
  • Fig. 69 Norway market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 70 Asia Pacific
  • Fig. 71 Asia Pacific market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 72 China
  • Fig. 73 China market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 74 Japan
  • Fig. 75 Japan market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 76 India
  • Fig. 77 India market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 79 Thailand
  • Fig. 80 Thailand market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 81 South Korea
  • Fig. 82 South Korea market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 85 Latin America
  • Fig. 86 Latin America market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 87 Brazil
  • Fig. 88 Brazil market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 101 Market share of key market players- Minimal Residual Disease Testing